drugset
drugset / Trial / NCT05602207

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

NCT05602207 ↗

Phase 4 Completed 24 enrolled Innovaderm Research Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.

Timeline

Start
2022-11-25
Primary completion
2024-12-03
Completion
2025-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abrocitinib Small molecule 100 mg —

Indications

atopic eczema